Morepen Laboratories shares climbed to a multi-year high of ₹112.85 on Wednesday, fueled by a 394% year-on-year surge in Q1 FY27 net profit. The company's successful transition toward high-value contract manufacturing, highlighted by a major ₹825 crore mandate, has significantly boosted investor sentiment. While the stock has seen strong gains, investors are now tracking margin sustainability and the execution of ongoing projects ahead of the company's upcoming annual general meeting.
Morepen Laboratories hit a multi-year high on Wednesday, with the stock price touching ₹112.85. This strong market reaction follows the company's first-quarter results for fiscal year 2027, which showed a significant improvement in financial performance. Investors have reacted to a triple-digit growth in profitability, as the firm reported a consolidated net profit of ₹56.35 crore, a 394% jump compared to the same quarter last year.
The company also recorded its highest-ever quarterly revenue of ₹575.31 crore, representing a 34% increase year-on-year. This growth is being attributed to a strategic shift in the company's business model. Morepen is moving away from its traditional, lower-margin bulk drug (API) business toward a more specialized approach involving Contract Development and Manufacturing Organizations, often referred to as CDMOs. In this business model, the company acts as a manufacturing partner for other pharmaceutical brands, which often provides more stable and predictable revenue.
A key driver of this performance is a large ₹825 crore CDMO mandate that has now entered its commercial stage. During the recent quarter, this project contributed ₹58 crore in revenue, acting as a proof-of-concept for the company’s new strategy. This pivot has also had a visible impact on profitability. The company’s operating margin (EBITDA margin) improved to 15.25% in the first quarter of fiscal year 2027, up from 6.65% in the same period last year. This change indicates that the company is becoming more efficient at turning its revenue into actual profit.
However, investors should be mindful of the risks associated with such rapid growth. While the shift to CDMO services is promising, it relies heavily on successful long-term execution and the ability to retain key clients. If the company faces delays in scaling these specialized manufacturing projects or if raw material costs rise, the improved profit margins could face pressure. Furthermore, stocks that experience such rapid price appreciation often see increased volatility, and retail investors should remain cautious about the sustainability of these moves in the short term.
Looking ahead, the next important monitorable for shareholders is the company's operational execution. The firm is preparing for its 41st Annual General Meeting scheduled for September 26, 2026. The board has also declared a final dividend of ₹0.20 per share, with the record date set for September 19, 2026. Investors will likely track management commentary at the meeting to understand how the company plans to manage its debt and capital spending while maintaining this new growth trajectory in the competitive pharmaceutical sector.